Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

類似資料

• Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
  著者:: Rojas, Luis, 等
  出版事項: (2020)
• Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
  著者:: Simoens, Steven, 等
  出版事項: (2021)
• A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
  著者:: De Cock, Erwin, 等
  出版事項: (2016)
• Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
  著者:: Waller, Cornelius F., 等
  出版事項: (2021)
• The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review
  著者:: Van den Nest, Miriam, 等
  出版事項: (2019)